Aquisição de Anacinra 100 mg/0.67 ml sol inj ser 0.67 ml SC, Bussulfano 60 mg/10 ml sol inj fr 10 ml IV, Fluorouracilo 50 mg/ml sol inj fr 100 ml IA IV, Interferão Beta-1A (Avonex seringas) 6 M.U.I. pó sol inj fr IM, Lenvatinib 10 mg cáps (Lenvima), Leuprorrelina 45 mg pó sol inj ser SC, Ramucirumab 10 mg/ml sol inj fr 50 ml IV e Vinorrelbina 20 mg cáps

ID 11371892 · Portal BASE
Price
Base Price
€71,770 .00
Effective Price
€3,118 .00 -95.7%
Contract Details
Contract Type
Aquisição de bens móveis
Procedure
Ao abrigo de acordo-quadro (art.º 259.º)
CPV Code
33600000
Location
Portugal, Lisboa, Lisboa
Bidder Count
—
Winner
LILLY-PORTUGAL PRODUTOS FARMACÊUTICOS LDA
NIF 500165602
Company
Dates
Publication
25 Apr 2025
Celebration
01 Apr 2025
Contracting Entity
Centro Hospitalar Universitário Lisboa Central, EPE
NIF 508080142
Public body
Data Source
Portal BASE
Api · synced 2026-04-17
Risk Flags
Score 85 · HIGH RISK
A2 · Late Publication
A2_PUBLICATION_AFTER_CELEBRATION
HIGH
Publication Date
25 Apr 2025
Signing Date
01 Apr 2025
Days Late
24
Rule
A2/A3 late publication: 24 days after signing (threshold: 10)
Detected 2026-03-06
A5 · Threshold Splitting
A5_THRESHOLD_SPLITTING
MEDIUM
Base price
71770.0
Threshold
75000.0
Rule
A5 threshold splitting: price within 5% below 75000.0
Detected 2026-03-06
A9 · Abnormal Price Reduction
A9_PRICE_REDUCTION
LOW
Base price
71770.0
Total effective price
3118.0
Ratio
0.0434
Direction
reduction
Rule
A9 price reduction: ratio 0.0434 outside [0.5, 1.5]
Detected 2026-03-06